BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17283131)

  • 1. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).
    Markus J; Garin MT; Bies J; Galili N; Raza A; Thirman MJ; Le Beau MM; Rowley JD; Liu PP; Wolff L
    Cancer Res; 2007 Feb; 67(3):992-1000. PubMed ID: 17283131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
    Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
    Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
    Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
    Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
    Castilla LH; Bushweller JH
    Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
    Kim HG; Kojima K; Swindle CS; Cotta CV; Huo Y; Reddy V; Klug CA
    Blood; 2008 Feb; 111(3):1567-74. PubMed ID: 17967943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
    Richter L; Wang Y; Hyde RK
    Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
    Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
    Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for inv(16) AML.
    Surapally S; Tenen DG; Pulikkan JA
    Blood; 2021 May; 137(19):2579-2584. PubMed ID: 33821975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice.
    Yang Y; Wang W; Cleaves R; Zahurak M; Cheng L; Civin CI; Friedman AD
    Cancer Res; 2002 Apr; 62(8):2232-5. PubMed ID: 11956074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
    Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
    Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice.
    Wolff L; Garin MT; Koller R; Bies J; Liao W; Malumbres M; Tessarollo L; Powell D; Perella C
    Oncogene; 2003 Dec; 22(58):9265-74. PubMed ID: 14681685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia.
    Shimamoto T; Ohyashiki JH; Ohyashiki K
    Leuk Res; 2005 Jun; 29(6):653-9. PubMed ID: 15863205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to re-express epigenetically silenced p15(INK4b) and p21(WAF1) genes in acute myeloid leukemia.
    Geyer CR
    Epigenetics; 2010; 5(8):696-703. PubMed ID: 21124069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
    Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
    Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
    Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
    Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.
    Illendula A; Pulikkan JA; Zong H; Grembecka J; Xue L; Sen S; Zhou Y; Boulton A; Kuntimaddi A; Gao Y; Rajewski RA; Guzman ML; Castilla LH; Bushweller JH
    Science; 2015 Feb; 347(6223):779-84. PubMed ID: 25678665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
    Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
    Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing.
    Cameron EE; Baylin SB; Herman JG
    Blood; 1999 Oct; 94(7):2445-51. PubMed ID: 10498617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    Leukemia; 2003 Sep; 17(9):1813-9. PubMed ID: 12970781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes.
    Chen H; Wu S
    Chin Med J (Engl); 2002 Jul; 115(7):987-90. PubMed ID: 12150726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.